There are just 1,500 drug inspectors responsible for more than 10,000 factories in India
Ranbaxy, which is 63.5 per cent-owned by Japan's Daiichi Sankyo Co and gets more than 40 per cent of its sales from the United States, did not immediately respond to a request on Wednesday for comment on the FDA observations.
India on Monday raised serious concerns over the USFDA's audit inspections of Indian pharma companies and 'disproportionate penalties' in some instances and said it would submit a discussion document on the issues to the US.
Private lenders were among the top losers along with RIL.
A global policy would reward firms which strive for higher quality.
Do away with the table salt. A reduction in the intake of salt can help control various kidney problems.
Taking up heavy exercise without being conditioned for it may expose one to risks like rhabdo.
Competition in the US pharmaceutical market swelled in recent years, with increasing generic penetration.
'Unless India Inc's earnings offer promise in March 2017 quarter, sentiment may not reverse in a hurry.'
Broader market outperformed the headline indices with BSE Midcap and Smallcap finishing the day 1.22%, and 1.54% higher, respectively
While such buying could indicate confidence in the business, investors should do a comprehensive evaluation before getting into the stock.
Delhi's Connaught Place is the 6th most expensive location in the world.
The FDA has stepped up its efforts to ensure drug safety in recent months.
Hit by the new drug pricing policy and regulatory interventions, growth rate of the Rs 72,069-crore Indian pharmaceutical market has slowed down to 9.8 per cent in 2013 as compared to 16.6 per cent in 2012, says a report.
Airtel acquired African telecom operator Zain in 2010 for $10.7 billion.
Rise in crude oil price and rally in global equities aided the sentiment
Markets ended their lowest close in 2015 on fears of FII outflows as the US Fed may hike rates.
On October 2, a legislature committee wrote letters to the 14 companies, initiating an investigation and seeking details about recent price increases in several generic products available in the American market.
The positive bias was aided by metal, realty and auto indices
Over-expansion, bad management, and multiple allegations irreparably taint Malvinder and Shivinder Singh
Better-than-expected financial results in Q3 due to higher revenue growth and margins in key markets fuel the rally
The move assumes significance because a go-ahead from the US Food and Drug Administration for the new unit in Visakhapatnam is likely to give a huge boost to the company's revenues in upcoming quarters.
Most Asian markets ended with gains.
Once tipped to emerge as the biggest exporter, the pharmaceutical industry is yet to acquire the scale of those in software services, says Krishna Kant.
The India growth story is still intact, and fall in the Indian stock markets is an imported one and if the government succeeds in legislating the GST and Land Bill, India could yet emerge as a winner believe stock market experts
Import alert on Ranbaxy's Mohali unit; Strides' injectible arm gets warning letter
Analysts are eyeing bigger launches that will positively impact company's fortunes.
The rally in most of these stocks is partly attributed to impressive financial performance.
Many members of ministry panel give dissent note on clause; no clarity yet on whether it will apply to existing shares or new ones.
.jpg)
Banks, real estate and metal scrips among the top losers.
Index heavyweight RIL surged 3% to end above Rs 1,000 mark while IT majors were also the top gainers.
Natco Pharma, Wockhardt and Marksans have rallied between 50 and 70 per cent in the year till date.
The real challenge, says Subir Roy, is to go for something affordable whose quality is just right.
The broader markets ended firm with mid-caps and small-caps gaining nearly 0.5 per cent on the BSE.
The S&P BSE Sensex gained 115 points to end at 24,338 and the Nifty50 climbed 42 points to close at 7,404.
Infosys, TCS, HUL and Reliance Industries were the top gainers of the day.
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers' stock market queries. Ajit will offer his unbiased views on a weekly basis
Inspections only in domestic authorities' presence, visiting US drug regulator told
Gains were led by index heavyweights with Reliance Industries contributing the most.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances